New Approach to Combination Therapy in AMD

In this video from AAO 2016, Dr. Karl Csaky discusses outcomes from phase 1 studies evaluating the potential for combining an anti-VEGF with an Angiopoitin-2 (Ang2) inhibitor to treat wet AMD. One candidate under investigation is RG7716 (Roche/Genentech), a bispecific monoclonal antibody with anti-VEGF and anti-Ang2 Fab portions connected to a disabled Fc region. A second trial is evaluating a coformulation of aflibercept and nesvacumab (Regeneron), a fully humanized anti-Ang2 monoclonal antibody, in a single intravitreal injection. Dr. Csaky discusses early-stage trial results which show both drugs have a good safety profile and evidence of visual and anatomic improvements. A phase 2 trial is underway for RG7716 for both diabetic macular edema and wet AMD.